dualacting

Heron Therapeutics (NASDAQ:HRTX) on Tuesday said that the U.S. Food and Drug Administration (FDA) had acknowledged the receipt of the company’s prior approval supplement application for Zynrelef extended-release solution VAN. The company added that the FDA has assigned a PDUFA date of September 23, 2024. Press release. More on HeronContinue Reading